Ga onbeperkt met Magzter GOLD

Ga onbeperkt met Magzter GOLD

Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts

$149.99
 
$74.99/Jaar

Poging GOUD - Vrij

Innovation – The next frontier

Express Pharma

|

October 2020

Alok Ghosh, Ex-President - Global Technical Operations, Lupin, underscores the importance of creating a conducive environment to foster innovation in India’s life sciences sector to ensure its continuous progress

- Alok Ghosh

Innovation – The next frontier

The USFDA recently is-sued a guideline titled product Launch Notification under Section 506I. The guideline instructs companies to let the USFDA know if a product is not launched even after 180 days of getting approval. USFDA felt the need to issue this guideline on product launch since data shows that only about 40 per cent of generic products are getting launched after USFDA approval within a year. This means about 60 per cent of products are not getting launched after USFDA approval even after a year. The data also shows that even after five years about 30 per cent of products are not getting launched. Pharma companies spend a lot of money on development, bio studies, filing of product and pay GDUFA fees. Then, why are the products not launched even after approval? The answer is that there are way too many competitors marketing the same product thereby reducing the scope of marketing or the cost of the product is prohibitive to selling the product at a competitive price.

Essentially two developments have happened in the last couple of years:

1. The USFDA stepped up approval of products by introducing GDUFA and inducted a lot of new inspectors/reviewers to clear the backlogs of approval. From a backlog of more than 36 months once, one can expect approval of new product now in 12-14 months if the quality of filing and data is acceptable. This helped in more generic products getting approval, throwing the US market into intense competition.

2. The market consolidated in the US and from about 10-12 buyers, today about 90 per cent of buying are controlled effectively by three buyers only, namely – Red Oak, Walgreen- Boots Alliance & McKesson. This means the buyers have now very high bargaining power bringing price pressure on marketed products. It is now a win-win situation for both, the government and consumers in the US.

MEER VERHALEN VAN Express Pharma

Express Pharma

Express Pharma

NEEDLES, PENS AND PRESSURE THE GLP-1 CHALLENGE

As GLP-1 therapies transform diabetes and obesity care, demand for prefilled pens and injectors is soaring. Pharma-device collaborations, analytical innovation, and sustainable design will be key to tackle the growing device bottleneck

time to read

7 mins

November 2025

Express Pharma

Express Pharma

Unified standards and smarter design are key to unlocking next-generation HVAC performance

Current HVAC design relies on a diverse, and sometimes confusing, array of guidelines issued by regulatory bodies such as WHO, EU GMP, ISO 14644, ISPE Baseline, and ASHRAE/ISHRAE.

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Kyasanur Forest Disease - How far is a regulatory approved vaccine?

Dr Priyabrata Pattnaik, Former Deputy MD, Indian Immunologicals, informs about the Kyasanur Forest Disease (KFD), a zoonotic viral hemorrhagic fever endemic to parts of India, particularly along the Western Ghats and discusses the current status of developing a regulatory-approved KFD vaccine in India

time to read

3 mins

November 2025

Express Pharma

Express Pharma

India's biopharma industry charts the road from biosimilars to innovation

Express Pharma hosted the maiden Biopharma Leadership Conclave 2025 and brought together industry leaders to discuss how India can move from being the world's leading producer of generics and biosimilars to becoming a hub for innovative, affordable, and high-quality biologics and advanced therapies

time to read

4 mins

November 2025

Express Pharma

Express Pharma

Digital technologies are quietly transforming HVAC into an intelligent compliance partner

Over the last decade, HVAC standards in pharmaceutical manufacturing have undergone a quiet revolution.

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Direct-to-Retail will increasingly complement traditional pharma distribution

Aqualab has crossed Rs 100 crore in just three years, what have been the key drivers behind this growth, and how does the brand plan to achieve the Rs 250 crore target by FY25-26?Aqualab's journey to Rs 100 crore within three years reflects the strength of a simple yet powerful principle, accessibility through proximity. Our growth has been anchored in three areas: a high-velocity retail network that prioritises last-mile availability, a well-diversified therapeutic portfolio spanning acute and chronic segments, and a strong focus on brand trust built through consistent product quality.

time to read

3 mins

November 2025

Express Pharma

Express Pharma

Guaranteeing continuity of medicine supply through AI innovation

Hari Kiran Chereddi highlights how AI is transforming pharma supply chains to ensure uninterrupted medicine availability

time to read

2 mins

November 2025

Express Pharma

PROSOLV® 730: Directly compressible carrier for lipophilic ingredients

Nearly 90 % of molecules in the discovery pipeline and 40 % of drugs with market approval are poorly water soluble. Poor aqueous solubility can lead to low bioavailability resulting in insufficient plasma levels. Oil-based preparations of these APIs, as well as oily APIs in general, present challenges in terms of solid dosage form manufacturing. PROSOLV® 730 was designed to provide a solution to the formulation of BCS class II and IV APIs. It enables the formulation of lipidic APIs or API-loaded lipid systems by facilitating the adsorption of oil, creating a free-flowing, compactible system that can be further formulated. PROSOLV® 730 is a co-processed, high-functionality excipient comprising MCC SILICA COPOVIDONE

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Ensuring Clean Room Integrity with Prime Clean Reset High-Speed Doors: Minimizing Air Permeability and Leakages

High-speed doors for clean rooms are specialized industrial doors essential for maintaining controlled environments. These doors are engineered to be airtight, creating a reliable barrier between different areas of a facility. Their design ensures durability and minimal maintenance, reducing the frequency of repairs and replacements.

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Reimagining cold chain: How IoT secures every pharma mile

Swarup Bose, Co-founder and CEO, Celcius Logistics points out that as the demand for temperature-sensitive medicines surges, maintaining an unbroken cold chain has never been more critical. IoT is emerging as the game-changer that ensures every vial and vaccine arrives potent, safe, and on time

time to read

3 mins

November 2025

Translate

Share

-
+

Change font size